Description:
The cell and gene therapy (CGT) sector has experienced remarkable growth, with funding reaching $70 billion in 2021. As barriers to entry lower and the number of approved therapies with proven track records increases, over a thousand companies have entered or expanded within this dynamic field. Keeping up with this rapidly evolving industry is essential, and Kalorama Information’s latest report, Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers, IPOs, and Other Developments, 2022, provides comprehensive insights into the myriad deals shaping the CGT landscape.
Key Highlights:
- Funding and Investments: Detailed analysis of the financial influx into CGT-related companies, including IPOs, SPACs, venture capital, and private funding.
- Strategic Deals: Insight into mergers & acquisitions, strategic investments, technology and research collaborations, and licensing agreements.
- Operational Transactions: Examination of manufacturing and supply chain deals, public outreach efforts, consumer education, philanthropy, and distribution partnerships.
- Market Dynamics: Breakdown of restructurings, joint ventures, terminations, and spinoffs impacting the CGT sector.
- Quarterly Analysis: Charts illustrating the frequency and types of deals throughout 2021, providing a clear view of market trends and activity changes per quarter.
Why This Report is Essential:
- Comprehensive Coverage: Tracks hundreds of cell and gene therapy deals, categorizing them into a usable format for easy reference.
- Market Insight: Offers in-depth analysis of key deals and strategic movements within the CGT industry.
- Investor Guidance: Provides valuable information for investors looking to understand the funding landscape and identify opportunities.
Additional Features:
- Vendor Profiles: Detailed profiles of leading companies involved in the CGT market.
- Visual Data Representation: Charts and graphs that visually represent deal activities and trends.
- Expert Analysis: Insights from Kalorama’s experienced analysts, offering expert perspectives on market developments.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Total Quarterly Funding, By 2021 Quarter, By Type of Funding (in millions $) (%)
Category | Q1 | Q2 | Q3 | Q4 | Total | % |
M&A | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
VC/ Private | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
IPO/ FPO | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
SPAC | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
Strat. Investment* | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
Total | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | XX% |
Source: Kalorama Information